Fluoxetine Capsules vs. Tablets: Therapeutic Equivalence
Fluoxetine capsules and tablets are bioequivalent and can be used interchangeably in clinical practice without any adjustment in dosing or expected therapeutic outcomes. 1
Bioequivalence Evidence
Multiple rigorous bioequivalence studies demonstrate that fluoxetine tablets and capsules are therapeutically equivalent:
A randomized crossover study in 24 healthy subjects showed that fluoxetine tablets met FDA bioequivalence criteria, with 90% confidence intervals for both AUC and Cmax falling within the required 80-125% range for both fluoxetine (90% CI: 0.857-1.020 for AUC) and its active metabolite norfluoxetine (90% CI: 0.807-1.013 for AUC). 1
The point estimates for the geometric mean ratios were 0.935 for fluoxetine AUC and 0.904 for norfluoxetine AUC, indicating nearly identical absorption profiles between formulations. 1
Additional bioequivalence studies in different populations (Middle Eastern and Jordanian volunteers) confirmed interchangeability, with relative bioavailability of 98.94% and 90% confidence intervals consistently within FDA acceptance ranges. 2, 3
Practical Clinical Implications
There are no clinically meaningful differences in efficacy, side effects, or dosing between capsule and tablet formulations:
Both formulations produce identical plasma concentrations of fluoxetine and norfluoxetine at steady state, meaning therapeutic effects and adverse event profiles are equivalent. 1
The long half-life of fluoxetine (1-3 days) and norfluoxetine (4-16 days) means that even minor differences in absorption kinetics between formulations are clinically irrelevant, as steady-state concentrations are reached after 5-7 weeks regardless of formulation. 4, 5
Tolerability profiles are identical between formulations, with common side effects (nausea, nervousness, insomnia, headache) occurring at the same frequency. 1, 5
Dosing Considerations (Applicable to Both Formulations)
Standard starting dose is 20 mg daily in the morning for depression, with a therapeutic range of 20-60 mg/day producing plasma concentrations of 120-300 ng/mL (fluoxetine plus norfluoxetine). 6, 5
Higher doses (40-60 mg daily) may be required for OCD, though this increases adverse effect risk without necessarily improving outcomes for depression. 6, 7
CYP2D6 poor metabolizers require cautious dosing starting at 10 mg daily due to 3.9-11.5 fold higher drug exposure and significantly increased toxicity risk, including QT prolongation. 4, 7
Key Clinical Caveat
The formulation type (capsule vs. tablet) is irrelevant to clinical decision-making. The critical factors affecting fluoxetine therapy are dose, patient CYP2D6 metabolizer status, and drug interactions—not the physical form of the medication. 4, 7, 1